Worth reading
29Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
2000
¥100 million (annualized by fiscal 2028)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Partially revisedKey initiatives
01Streamline corporate functions
02Simplify processes by leveraging advanced technologies
03Prepare for the launch of multiple new products
04Advance the late-stage development pipeline
05Make strategic investments in advanced technologies
Risks identified by the company
Economic conditions surrounding Takeda's global operations, including general economic conditions in Japan and the United States and the status of international trade relations
The emergence and development of competing products
Changes in applicable laws and regulations, including drug pricing, tax, tariff and other trade-related regulations
The inherent difficulties of new product development, including uncertainty regarding clinical success and regulatory decisions and their timing
Uncertainty regarding the commercial success of new and existing products
Difficulties or delays in manufacturing
Fluctuations in interest rates and foreign exchange rates
Claims or concerns regarding the safety or efficacy of products marketed or product candidates
Health crises such as a novel coronavirus pandemic
The success of Takeda's environmental and sustainability initiatives in enabling reductions in greenhouse gas emissions or the achievement of other environmental goals
Initiatives to improve operational efficiency, enhance productivity or reduce costs, including the integration of digital technologies such as artificial intelligence (AI)
The extent to which other business restructuring initiatives contribute to the expected benefits
Reason for revision or withdrawal
To strengthen competitiveness, enhance long-term growth potential, and accelerate the launch of new products over the coming years.
| Item | Details |
|---|---|
| Plan name | The next step in the transformation |
| Plan period | FY2026-FY2028 |
| Progress against the plan | Partially revised |
| Key initiatives | Streamline corporate functions, Simplify processes by leveraging advanced technologies, Prepare for the launch of multiple new products, Advance the late-stage development pipeline, Make strategic investments in advanced technologies |
| Reason for revision or withdrawal | To strengthen competitiveness, enhance long-term growth potential, and accelerate the launch of new products over the coming years. |
| Risks identified | Economic conditions surrounding Takeda's global operations, including general economic conditions in Japan and the United States and the status of international trade relations, The emergence and development of competing products, Changes in applicable laws and regulations, including drug pricing, tax, tariff and other trade-related regulations, The inherent difficulties of new product development, including uncertainty regarding clinical success and regulatory decisions and their timing, Uncertainty regarding the commercial success of new and existing products, Difficulties or delays in manufacturing, Fluctuations in interest rates and foreign exchange rates, Claims or concerns regarding the safety or efficacy of products marketed or product candidates, Health crises such as a novel coronavirus pandemic, The success of Takeda's environmental and sustainability initiatives in enabling reductions in greenhouse gas emissions or the achievement of other environmental goals, Initiatives to improve operational efficiency, enhance productivity or reduce costs, including the integration of digital technologies such as artificial intelligence (AI), The extent to which other business restructuring initiatives contribute to the expected benefits |
| Date of board resolution | 25 March 2026 |
| Publication date | 25 March 2026 |
Items this document does not state (17)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planSize of the Target Market
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen competitiveness, enhance long-term growth potential, and accelerate the launch of new products over the coming years.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.